Weekly paclitaxel treatment of patients with progressive platinum resistant epithelial ovarian cancer.

被引：0
|
作者：
Le, T [1 ]
Baines, KA [1 ]
Rambout, L [1 ]
Rezaifer, P [1 ]
Al Hayki, M [1 ]
Hopkins, L [1 ]
Fung, MFK [1 ]
机构：
[1] Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：488S / 488S
页数：1
相关论文
共 50 条
  • [21] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [22] Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
    Cannistra, S. A.
    Matulonis, U.
    Penson, R.
    Wenham, R.
    Armstrong, D.
    Burger, R. A.
    Mackey, H.
    Douglas, J.
    Hambleton, J.
    McGuire, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 257S - 257S
  • [23] Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer
    Le, T.
    Hopkins, L.
    Baines, K. A.
    Rambout, L.
    Fung-Kee-Fung, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (03) : 428 - 431
  • [24] Weekly gemcitabine in patients with relapsed platinum-resistant ovarian or peritoneal cancer. Results of phase II study
    Czerniawska, Malgorzata
    Jagiello-Gruszfeld, Agnieszka
    Zbrzezniak, Jolanta
    Wachula, Ewa
    Szablowska-Siwik, Sylwia
    Sikorska, Magdalena
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
  • [25] A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Grisham, Rachel N.
    Gordon, Michael S.
    Harb, Wael A.
    Aghajanian, Carol
    McMeekin, D. Scott
    McKinley, Kristin
    Anderson, Lisa Renee
    Chavira, Renae
    Christy-Bittel, Janna
    Barrett, Emma
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Weekly paclitaxel in the treatment of recurrent ovarian cancer
    Richard D. Baird
    David S. P. Tan
    Stan B. Kaye
    Nature Reviews Clinical Oncology, 2010, 7 : 575 - 582
  • [27] Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.
    Wenham, Robert Michael
    Apte, Sachin M.
    Shahzad, Mian M.
    Lee, Jae K.
    Dorman, Denise
    Chon, Hye Sook
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Weekly paclitaxel in the treatment of recurrent ovarian cancer
    Baird, Richard D.
    Tan, David S. P.
    Kaye, Stan B.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (10) : 575 - 582
  • [29] Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer
    Lissianskaya, A
    Gershanovich, M
    Ognerubov, N
    Golubeva, O
    Pratt, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 460S - 460S
  • [30] PEMBROLIZUMAB AND BEVACIZUMAB IN PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS
    Michels, Judith
    Frenel, Jean-Sebastien
    Genestie, Catherine
    Ghiringhelli, Francois
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Balleyguier, Corinne
    Paci, Angelo
    Ciccolini, Joseph
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Pautier, Patricia
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A382 - A382
12345